- Report
- May 2025
- 150 Pages
Global
From €5261EUR$5,950USD£4,538GBP
- Report
- May 2025
- 199 Pages
Global
From €3135EUR$3,545USD£2,704GBP
€3483EUR$3,939USD£3,004GBP
- Report
- May 2025
- 191 Pages
Global
From €3135EUR$3,545USD£2,704GBP
€3483EUR$3,939USD£3,004GBP
- Report
- April 2025
- 175 Pages
Global
From €3970EUR$4,490USD£3,425GBP
- Report
- February 2025
- 200 Pages
Global
From €3970EUR$4,490USD£3,425GBP
- Report
- April 2025
- 175 Pages
Global
From €3970EUR$4,490USD£3,425GBP
- Report
- April 2025
- 175 Pages
Global
From €3970EUR$4,490USD£3,425GBP
- Report
- January 2025
- 175 Pages
Global
From €3970EUR$4,490USD£3,425GBP
- Report
- January 2025
- 175 Pages
Global
From €3970EUR$4,490USD£3,425GBP
- Report
- January 2025
- 175 Pages
Global
From €3970EUR$4,490USD£3,425GBP
- Report
- April 2025
- 150 Pages
Global
From €2874EUR$3,250USD£2,479GBP
€4288EUR$4,850USD£3,699GBP
- Report
- July 2025
- 383 Pages
Global
From €5172EUR$5,850USD£4,462GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1326EUR$1,500USD£1,144GBP
- Report
- June 2025
- 150 Pages
Global
From €2386EUR$2,699USD£2,059GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2466EUR$2,789USD£2,127GBP
- Report
- May 2024
- 129 Pages
Global
From €5746EUR$6,499USD£4,957GBP
- Report
- May 2024
- 137 Pages
Global
From €5746EUR$6,499USD£4,957GBP
- Report
- January 2022
- 60 Pages
Global
From €1326EUR$1,500USD£1,144GBP
- Report
- March 2024
- 134 Pages
Global
From €7029EUR$7,950USD£6,064GBP
- Report
- April 2020
- 125 Pages
Global
From €2589EUR$2,928USD£2,233GBP
€3236EUR$3,660USD£2,792GBP

Erythropoiesis Stimulating Agents (ESAs) are a class of drugs used to treat anemia, a condition in which the body does not produce enough red blood cells. ESAs stimulate the production of red blood cells in the bone marrow, increasing the amount of oxygen-carrying hemoglobin in the blood. ESAs are used to treat anemia caused by chemotherapy, chronic kidney disease, and other conditions. They are also used to reduce the need for blood transfusions in certain patients.
ESAs are a major component of the hematological drugs market, which includes drugs used to treat blood-related diseases and disorders. The market is driven by the increasing prevalence of anemia and other blood-related disorders, as well as the development of new drugs and treatments.
Some companies in the ESA market include Amgen, Johnson & Johnson, Roche, Novartis, and Pfizer. Show Less Read more